A Study of ARRY-371797 in Patients With Rheumatoid Arthritis

Completed · Phase 1 · Has a placebo group

Conditions studied: Rheumatoid Arthritis

In brief

This is a Phase 1 study, involving a 29-day treatment period, designed to evaluate the pharmacokinetics and the effectiveness of investigational study drug ARRY-371797 in treating rheumatoid arthritis in patients receiving stable doses of methotrexate, and to further evaluate the drug's safety. Approximately 30 patients from the US will be enrolled in this study.

Key facts

Study ID

NCT00729209

Run by

Array Biopharma, now a wholly owned subsidiary of Pfizer

People needed

28

Starts

2008-07-01

Expected to finish

2009-04-01

Last updated by the study team

2020-09-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Clinic for Rheumatic Diseases — Tuscaloosa, Alabama, United States
• Sun Valley Arthritis Center, Ltd — Peoria, Arizona, United States
• Woodland International Research Group — Little Rock, Arkansas, United States
• NUCATS Institute, Northwestern University — Chicago, Illinois, United States
• Lynn Health Sciences Institute — Oklahoma City, Oklahoma, United States
• Metroplex Clinical Research Center — Dallas, Texas, United States
• Sentara Clinical Research Group — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.